Use of antisecretory drugs among consumers of non‐steroidal anti‐inflammatory drugs in the general population
Open Access
- 28 November 2006
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 24 (11-12) , 1585-1592
- https://doi.org/10.1111/j.1365-2036.2006.03173.x
Abstract
Summary: Background Overall success of prophylactic strategies against non‐steroidal anti‐inflammatory drug (NSAID) complications depends on the use of gastroprotective drugs.Aim We examined the use of antisecretory drugs in NSAID users in the general population of Spain.Participants and Methods In 2002, a phone interview was conducted with 2500 persons representative of the general population of Spain. Using a validated questionnaire, we asked about the use of NSAID, aspirin and antisecretory drugs, and history of digestive diseases. We estimated the use of antisecretory drugs in NSAID users, according to risk factors for gastrointestinal (GI) lesions associated with NSAID.Results In total, 425 persons [17.0% (95% CI 15.5–18.5%)] were NSAID users. Of them, 69 persons (16.2%; 95% CI 12.7–19.7%) used antisecretory drugs [proton pump inhibitor (PPI) 11.8% and H2‐blocker 4.9%]. Forty‐four of the 224 NSAID users (19.6%) with one risk factor for GI lesions were antisecretory drug users (PPI 16%; H2‐blocker 4%), compared with 24 of the 197 NSAID users (12.7%) without risk factors (PPI 6.6%; H2‐blocker 6.1%). NSAID users with risk factors for GI lesions but without upper GI (UGI) symptoms did not consume more antisecretory drugs than equivalent non‐NSAID users (12.9% vs. 10.7%).Conclusion Current strategies to prevent GI lesions in NSAID users are not effective from a population perspective, especially in subjects without UGI symptoms.Keywords
This publication has 25 references indexed in Scilit:
- Prevalence of atypical symptoms and their association with typical symptoms of gastroesophageal reflux in SpainEuropean Journal of Gastroenterology & Hepatology, 2006
- National Adherence to Evidence-Based Guidelines for the Prescription of Nonsteroidal Anti-Inflammatory DrugsGastroenterology, 2005
- Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damageInternational Journal Of Clinical Practice, 2005
- Frequent monthly use of selected non-prescription and prescription non-narcotic analgesics among U.S. adultsPharmacoepidemiology and Drug Safety, 2004
- Medical Consultation for Gastro-Oesophageal Reflux Symptoms: Reasons and Associated FactorsDigestion, 2004
- Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish populationAlimentary Pharmacology & Therapeutics, 2003
- Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideosGastroenterología y Hepatología, 2003
- NSAIDs, gastroprotection and cyclo‐oxygenase‐II‐selective inhibitors*Alimentary Pharmacology & Therapeutics, 2003
- The iatrogenic costs of NSAID therapy: A population studyArthritis & Rheumatism, 2002
- A New Questionnaire for Gastroesophageal Reflux DiseaseMayo Clinic Proceedings, 1994